About
Clinical-stage oncology company with a lead program in US-based phase II trials for brain cancer
Areas of Focus
Categories
Small Molecule PharmaceuticalAustralia
Team (11)
Clinical Trials (13)
View allTotal Trials
13
As Lead Sponsor
5
As Collaborator
8
Total Enrollment
1,837
By Phase
PHASE1/PHASE2: 1PHASE2: 5PHASE1: 6PHASE2/PHASE3: 1
By Status
COMPLETED: 6RECRUITING: 4ACTIVE_NOT_RECRUITING: 2SUSPENDED: 1
Clinical Trials Pipeline13 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
Today
Hover over trial bars to see details
Recent Trials
NCT06208657Collaborator
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
PHASE1/PHASE2Recruiting
82 participants
Started: Jul 10, 2024 · Completed: Dec 31, 2035
NCT05183204Collaborator
Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
PHASE2Recruiting
33 participants
Started: Feb 14, 2022 · Completed: Dec 31, 2025
NCT05114668Lead Sponsor
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
PHASE1Completed
32 participants
Started: Nov 3, 2021 · Completed: Nov 22, 2024
NCT05012670Lead Sponsor
Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects
PHASE1Completed
6 participants
Started: Aug 18, 2021 · Completed: Jan 30, 2024
NCT04906096Collaborator
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
PHASE2Recruiting
25 participants
Started: Jun 1, 2021 · Completed: Dec 1, 2027
Locations (1)
Headquarters
Sydney, Australia
Map
Loading map...